Tardive Dyskinesia Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2023-2032), Analyzes DelveInsight | Auspex Pharma, Neurocrine Biosciences, Teva Pharma, UCB Pharma

Posted on
by

Tardive Dyskinesia Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2023-2032), Analyzes DelveInsight | Auspex Pharma, Neurocrine Biosciences, Teva Pharma, UCB Pharma
DelveInsight’s “Tardive Dyskinesia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Tardive Dyskinesia.

DelveInsight’s “Tardive Dyskinesia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Tardive Dyskinesia, historical and forecasted epidemiology as well as the Tardive Dyskinesia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Tardive Dyskinesia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Tardive Dyskinesia Market Forecast

 

Some of the key facts of the Tardive Dyskinesia Market Report: 

  • The Tardive Dyskinesia market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • Once Tardive Dyskinesia manifests, some effects could be long-lasting or take a while to disappear. Age, the length of time taking dopamine receptor blockers (DRB), and a history of drug or alcohol use are all known risk factors for developing Tardive Dyskinesia
  • The Mental Health America (MIIA) estimates that at least 500,000 persons in the US are affected by TD. Particularly at risk are people who have received treatment for bipolar disorder, schizoaffective disorder, or schizophrenia. A person is more prone to acquire persistent and irreversible tardive dyskinesia as they age
  • The average prevalence of tardive dyskinesia is expected to be at least 20% of all patients who were treated with first-generation neuroleptics, according to a 2020 study named “Tardive Dyskinesia” by Vasan et al.
  • Key Tardive Dyskinesia Companies: SOM Biotech, Cycle Pharmaceuticals, Mitsubishi Tanabe Pharma, Auspex Pharma, Neurocrine Biosciences, Teva Pharma, UCB Pharma, Ipsen, Caroff, and others
  • Key Tardive Dyskinesia Therapies: SOM3366, Zydis ODT, MT-5199, SD-809, Valbenazine, SD-809, levetiracetam, AbobotulinumtoxinA, Galantamine, and others
  • The Tardive Dyskinesia epidemiology based on gender analyzed that Tardive Dyskinesia occurs more commonly in females as compared to males
  • The Tardive Dyskinesia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Tardive Dyskinesia pipeline products will significantly revolutionize the Tardive Dyskinesia market dynamics.

 

Tardive Dyskinesia Overview

Tardive dyskinesia (TD), a neurological movement disease that is involuntary, is brought on by the use of dopamine receptor blockers that are recommended to treat specific psychiatric or digestive conditions, according to the National Organisation for Rare Disorders (NORD).

 

Get a Free sample for the Tardive Dyskinesia Market Report 

https://www.delveinsight.com/report-store/tardive-dyskinesia-market

 

Tardive Dyskinesia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Tardive Dyskinesia Epidemiology Segmentation:

The Tardive Dyskinesia market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Tardive Dyskinesia
  • Prevalent Cases of Tardive Dyskinesia by severity
  • Gender-specific Prevalence of Tardive Dyskinesia
  • Diagnosed Cases of Episodic and Chronic Tardive Dyskinesia

 

Download the report to understand which factors are driving Tardive Dyskinesia epidemiology trends @ Tardive Dyskinesia Epidemiology Forecast

 

Tardive Dyskinesia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Tardive Dyskinesia market or expected to get launched during the study period. The analysis covers Tardive Dyskinesia market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Tardive Dyskinesia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Tardive Dyskinesia Therapies and Key Companies

  • SOM3366: SOM Biotech
  • Zydis ODT: Cycle Pharmaceuticals
  • MT-5199: Mitsubishi Tanabe Pharma
  • SD-809: Auspex Pharma
  • Valbenazine: Neurocrine Biosciences
  • SD-809: Teva Pharma
  • levetiracetam: UCB Pharma
  • AbobotulinumtoxinA: Ipsen
  • Galantamine: Caroff

 

Discover more about therapies set to grab major Tardive Dyskinesia market share @ Tardive Dyskinesia Treatment Market

 

Scope of the Tardive Dyskinesia Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Tardive Dyskinesia Companies: SOM Biotech, Cycle Pharmaceuticals, Mitsubishi Tanabe Pharma, Auspex Pharma, Neurocrine Biosciences, Teva Pharma, UCB Pharma, Ipsen, Caroff, and others
  • Key Tardive Dyskinesia Therapies: SOM3366, Zydis ODT, MT-5199, SD-809, Valbenazine, SD-809, levetiracetam, AbobotulinumtoxinA, Galantamine, and others
  • Tardive Dyskinesia Therapeutic Assessment: Tardive Dyskinesia current marketed and Tardive Dyskinesia emerging therapies
  • Tardive Dyskinesia Market Dynamics: Tardive Dyskinesia market drivers and Tardive Dyskinesia market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Tardive Dyskinesia Unmet Needs, KOL’s views, Analyst’s views, Tardive Dyskinesia Market Access and Reimbursement 

 

To know more about Tardive Dyskinesia companies working in the treatment market, visit @ Tardive Dyskinesia Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Tardive Dyskinesia Market Report Introduction

2. Executive Summary for Tardive Dyskinesia

3. SWOT analysis of Tardive Dyskinesia

4. Tardive Dyskinesia Patient Share (%) Overview at a Glance

5. Tardive Dyskinesia Market Overview at a Glance

6. Tardive Dyskinesia Disease Background and Overview

7. Tardive Dyskinesia Epidemiology and Patient Population

8. Country-Specific Patient Population of Tardive Dyskinesia 

9. Tardive Dyskinesia Current Treatment and Medical Practices

10. Tardive Dyskinesia Unmet Needs

11. Tardive Dyskinesia Emerging Therapies

12. Tardive Dyskinesia Market Outlook

13. Country-Wise Tardive Dyskinesia Market Analysis (2019–2032)

14. Tardive Dyskinesia Market Access and Reimbursement of Therapies

15. Tardive Dyskinesia Market Drivers

16. Tardive Dyskinesia Market Barriers

17.  Tardive Dyskinesia Appendix

18. Tardive Dyskinesia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services